Baseline characteristics stratified according to the occurrence of pulmonary embolism
| Variable . | PE . | |||
|---|---|---|---|---|
| No (N = 3128) . | Yes (N = 219) . | Total (N = 3347) . | Missing (%) . | |
| Agea | 54.1 ± 19.5 | 61.6 ± 16.7 | 54.6 ± 19.4 | 0.3 |
| Sex (female) | 1800 (57.5%) | 110 (50.2%) | 1910 (57.1%) | — |
| Systolic blood pressure | 134 (119–151) | 136 (119–151) | 134 (119–151) | 6.7 |
| Diastolic blood pressure | 77 (67–87) | 79 (69–89) | 77 (67–87) | 6.5 |
| Temperature | 36.6 ± 1.3 | 36.7 ± 0.7 | 36.6 ± 1.3 | 10.2 |
| Heart ratea | 86.1 ± 20.3 | 92.1 ± 20.1 | 86.5 ± 20.3 | 5.6 |
| Respiratory rate | 12.7 ± 5.9 | 13.1 ± 5.3 | 12.7 ± 5.9 | 7.9 |
| O2 saturationa | 96.8 ± 3.2 | 95.3 ± 3.8 | 96.7 (3.2) | 6.5 |
| Clinical signs and symptoms of DVTa | 358 (11.9%) | 48 (23.6%) | 406 (12.7%) | 4.3 |
| Alternative diagnosis equal or more likely than PEa | 986 (82.0%) | 27 (45.8%) | 1013 (80.3%) | 62 |
| Haemoptysisa | 152 (5.2%) | 15 (7.2%) | 167(5.3%) | 6.1 |
| Immobilization/surgerya | 328 (11.7%) | 63 (33.5%) | 391 (13.1%) | 9 |
| Previous DVT/PEa | 364 (12.0%) | 58 (27.8%) | 422 (13.1%) | 3.5 |
| Malignancya | 72 (2.7%) | 7 (3.7%) | 79 (2.8%) | 14.3 |
| Oestrogen usea | 188 (6.5%) | 15 (7.5%) | 203 (6.5%) | 7.3 |
| Tender on palpationa | 222 (7.5%) | 33 (16.5%) | 255 (8.0%) | 5.3 |
| Lower limb paina | 268 (8.9%) | 36 (17.1%) | 304 (9.5%) | 4 |
| Lower leg swella | 62 (2.1%) | 11 (5.8%) | 73 (2.4%) | 7.7 |
| D-dimer (ng/mL)a | 252 (142–502) | 1000 (690–1000) | 273 (148–593) | 0 |
| Variable . | PE . | |||
|---|---|---|---|---|
| No (N = 3128) . | Yes (N = 219) . | Total (N = 3347) . | Missing (%) . | |
| Agea | 54.1 ± 19.5 | 61.6 ± 16.7 | 54.6 ± 19.4 | 0.3 |
| Sex (female) | 1800 (57.5%) | 110 (50.2%) | 1910 (57.1%) | — |
| Systolic blood pressure | 134 (119–151) | 136 (119–151) | 134 (119–151) | 6.7 |
| Diastolic blood pressure | 77 (67–87) | 79 (69–89) | 77 (67–87) | 6.5 |
| Temperature | 36.6 ± 1.3 | 36.7 ± 0.7 | 36.6 ± 1.3 | 10.2 |
| Heart ratea | 86.1 ± 20.3 | 92.1 ± 20.1 | 86.5 ± 20.3 | 5.6 |
| Respiratory rate | 12.7 ± 5.9 | 13.1 ± 5.3 | 12.7 ± 5.9 | 7.9 |
| O2 saturationa | 96.8 ± 3.2 | 95.3 ± 3.8 | 96.7 (3.2) | 6.5 |
| Clinical signs and symptoms of DVTa | 358 (11.9%) | 48 (23.6%) | 406 (12.7%) | 4.3 |
| Alternative diagnosis equal or more likely than PEa | 986 (82.0%) | 27 (45.8%) | 1013 (80.3%) | 62 |
| Haemoptysisa | 152 (5.2%) | 15 (7.2%) | 167(5.3%) | 6.1 |
| Immobilization/surgerya | 328 (11.7%) | 63 (33.5%) | 391 (13.1%) | 9 |
| Previous DVT/PEa | 364 (12.0%) | 58 (27.8%) | 422 (13.1%) | 3.5 |
| Malignancya | 72 (2.7%) | 7 (3.7%) | 79 (2.8%) | 14.3 |
| Oestrogen usea | 188 (6.5%) | 15 (7.5%) | 203 (6.5%) | 7.3 |
| Tender on palpationa | 222 (7.5%) | 33 (16.5%) | 255 (8.0%) | 5.3 |
| Lower limb paina | 268 (8.9%) | 36 (17.1%) | 304 (9.5%) | 4 |
| Lower leg swella | 62 (2.1%) | 11 (5.8%) | 73 (2.4%) | 7.7 |
| D-dimer (ng/mL)a | 252 (142–502) | 1000 (690–1000) | 273 (148–593) | 0 |
DVT, deep venous thrombosis; PE, pulmonary embolism. aVariables in machine learning models.
Baseline characteristics stratified according to the occurrence of pulmonary embolism
| Variable . | PE . | |||
|---|---|---|---|---|
| No (N = 3128) . | Yes (N = 219) . | Total (N = 3347) . | Missing (%) . | |
| Agea | 54.1 ± 19.5 | 61.6 ± 16.7 | 54.6 ± 19.4 | 0.3 |
| Sex (female) | 1800 (57.5%) | 110 (50.2%) | 1910 (57.1%) | — |
| Systolic blood pressure | 134 (119–151) | 136 (119–151) | 134 (119–151) | 6.7 |
| Diastolic blood pressure | 77 (67–87) | 79 (69–89) | 77 (67–87) | 6.5 |
| Temperature | 36.6 ± 1.3 | 36.7 ± 0.7 | 36.6 ± 1.3 | 10.2 |
| Heart ratea | 86.1 ± 20.3 | 92.1 ± 20.1 | 86.5 ± 20.3 | 5.6 |
| Respiratory rate | 12.7 ± 5.9 | 13.1 ± 5.3 | 12.7 ± 5.9 | 7.9 |
| O2 saturationa | 96.8 ± 3.2 | 95.3 ± 3.8 | 96.7 (3.2) | 6.5 |
| Clinical signs and symptoms of DVTa | 358 (11.9%) | 48 (23.6%) | 406 (12.7%) | 4.3 |
| Alternative diagnosis equal or more likely than PEa | 986 (82.0%) | 27 (45.8%) | 1013 (80.3%) | 62 |
| Haemoptysisa | 152 (5.2%) | 15 (7.2%) | 167(5.3%) | 6.1 |
| Immobilization/surgerya | 328 (11.7%) | 63 (33.5%) | 391 (13.1%) | 9 |
| Previous DVT/PEa | 364 (12.0%) | 58 (27.8%) | 422 (13.1%) | 3.5 |
| Malignancya | 72 (2.7%) | 7 (3.7%) | 79 (2.8%) | 14.3 |
| Oestrogen usea | 188 (6.5%) | 15 (7.5%) | 203 (6.5%) | 7.3 |
| Tender on palpationa | 222 (7.5%) | 33 (16.5%) | 255 (8.0%) | 5.3 |
| Lower limb paina | 268 (8.9%) | 36 (17.1%) | 304 (9.5%) | 4 |
| Lower leg swella | 62 (2.1%) | 11 (5.8%) | 73 (2.4%) | 7.7 |
| D-dimer (ng/mL)a | 252 (142–502) | 1000 (690–1000) | 273 (148–593) | 0 |
| Variable . | PE . | |||
|---|---|---|---|---|
| No (N = 3128) . | Yes (N = 219) . | Total (N = 3347) . | Missing (%) . | |
| Agea | 54.1 ± 19.5 | 61.6 ± 16.7 | 54.6 ± 19.4 | 0.3 |
| Sex (female) | 1800 (57.5%) | 110 (50.2%) | 1910 (57.1%) | — |
| Systolic blood pressure | 134 (119–151) | 136 (119–151) | 134 (119–151) | 6.7 |
| Diastolic blood pressure | 77 (67–87) | 79 (69–89) | 77 (67–87) | 6.5 |
| Temperature | 36.6 ± 1.3 | 36.7 ± 0.7 | 36.6 ± 1.3 | 10.2 |
| Heart ratea | 86.1 ± 20.3 | 92.1 ± 20.1 | 86.5 ± 20.3 | 5.6 |
| Respiratory rate | 12.7 ± 5.9 | 13.1 ± 5.3 | 12.7 ± 5.9 | 7.9 |
| O2 saturationa | 96.8 ± 3.2 | 95.3 ± 3.8 | 96.7 (3.2) | 6.5 |
| Clinical signs and symptoms of DVTa | 358 (11.9%) | 48 (23.6%) | 406 (12.7%) | 4.3 |
| Alternative diagnosis equal or more likely than PEa | 986 (82.0%) | 27 (45.8%) | 1013 (80.3%) | 62 |
| Haemoptysisa | 152 (5.2%) | 15 (7.2%) | 167(5.3%) | 6.1 |
| Immobilization/surgerya | 328 (11.7%) | 63 (33.5%) | 391 (13.1%) | 9 |
| Previous DVT/PEa | 364 (12.0%) | 58 (27.8%) | 422 (13.1%) | 3.5 |
| Malignancya | 72 (2.7%) | 7 (3.7%) | 79 (2.8%) | 14.3 |
| Oestrogen usea | 188 (6.5%) | 15 (7.5%) | 203 (6.5%) | 7.3 |
| Tender on palpationa | 222 (7.5%) | 33 (16.5%) | 255 (8.0%) | 5.3 |
| Lower limb paina | 268 (8.9%) | 36 (17.1%) | 304 (9.5%) | 4 |
| Lower leg swella | 62 (2.1%) | 11 (5.8%) | 73 (2.4%) | 7.7 |
| D-dimer (ng/mL)a | 252 (142–502) | 1000 (690–1000) | 273 (148–593) | 0 |
DVT, deep venous thrombosis; PE, pulmonary embolism. aVariables in machine learning models.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
